首页> 外文期刊>European Journal of Cancer Supplements >803 ORAL Doppler ultrasonography with perfusion software and contrast agent injection as an early evaluation tool of metastatic renal cancers treated with the RAF kinase and VEGFR inhibitor: a prospective study

【24h】

803 ORAL Doppler ultrasonography with perfusion software and contrast agent injection as an early evaluation tool of metastatic renal cancers treated with the RAF kinase and VEGFR inhibitor: a prospective study

机译：803口服多普勒超声检查与灌注软件和造影剂注射作为RAF激酶和VEGFR抑制剂治疗的转移性肾癌的早期评估工具：一项前瞻性研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. 1008 POSTER Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification for the early evaluation of metastatic renal cancer treated with tyrosine kinase inhibitors [J] . L.Bouaita, N.Lassau, S.Koscielny, European Journal of Cancer Supplements . 2007,第4期

机译：1008 POSTER动态定量超声检查（DCE-US），定量分析，用于酪氨酸激酶抑制剂治疗的转移性肾癌的早期评估
2. Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: a prospective phase II study. [J] . Lamuraglia M, Lassau N, Garbay JR, European Journal of Radiology . 2005,第3期

机译：多普勒超声与灌注软件和造影剂注射在早期评估乳腺癌复发中的射频：一项前瞻性II期研究。
3. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. [J] . Lassau N, Lamuraglia M, Vanel D, Annals of oncology: official journal of the European Society for Medical Oncology . 2005,第7期

机译：多普勒超声结合灌注软件和造影剂注射对肢体肉瘤孤立性肢体灌注的早期评估：49例前瞻性研究。
4. A first‐in‐human phase I multicenter open‐label dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status [O] . Benjamin Izar, William Sharfman, F. Stephen Hodi, 2017

机译：口服RAF / VEGFR-2抑制剂（RAF265）在BRAF突变状态独立的局部晚期或转移性黑色素瘤中的首次人类I期多中心开放标签剂量递增研究
5. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status [O] . Izar, Benjamin, Sharfman, William, Hodi, F Stephen, 2017

机译：口服RAF / VEGFR-2抑制剂（RAF265）在BRAF突变状态独立的局部晚期或转移性黑色素瘤中的首次人类I期，多中心，开放标签，剂量递增研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号